Shuo Ma

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Chronic Lymphocytic Leukemia

Dna Methylation

Top Venues

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)
Wei Xu, Ke-Shu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Han Yan, Wei Zhang, Kaiyang Ding, Jian-Feng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jian-da Hu, Chun-Yan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. American journal of hematology 98 (4) (2023)